Skip to main content
OpenTrials
Completed

NCT Number: NCT04599868

High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa.

To assess the efficacy and safety of alternative magnesium sulfate regimens when used as single agent tocolytic therapy for prevention of preterm labour in patients with symptomatic placenta previa and subsequent changes in the cervical length .

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Assiut University

Asyut, 71111, Egypt

About this study

Placenta previa is implantation of placenta on or near internal os .It is classified into major degree when lower edge of placenta lies within 2 cm from internal os , and minor degree if lower edge of placenta at lower uterine segment but more than 2 cm from internal os .

There are many risk factors for developing placenta previa including multi parity , multiple pregnancy , increased maternal age (>35y ) , previous uterine surgery , history of placenta previa (4-8%) .

A significant degree of uterine contractility has been observed with symptomatic placenta previa. It is directly associated with vaginal bleeding. However, a large percentage of women who have placenta previa associated with haemorrhage will experience subclinical uterine contractions before the onset of overt vaginal bleeding. Therefore, the use of tocolytic agents in management of placenta previa seems reasonable .

Magnesium sulfate alters calcium up take, binding and distribution in smooth muscles of the uterus, so reduces the frequency of cell depolarization and inhibits myometrial contraction .

In addition to its tocolytic action magnesium sulfate also provide neuroprotection to preterm infant . .

At women Health Hospital, Assiut University, Egypt our policy is using magnesium sulfate as first line for tocolysis for placenta previa patients with preterm uterine contractions. By giving a loading dose of 4 g on 150 ml saline intravenous infusion over 20 minutes, and a maintenance dose of 6g/6h on 500 ml saline slow intra venous infusion

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy.
  • Gestational age between 28 weeks to 37 weeks.
  • Patients presented to the hospital with per vaginal bleeding and in whom a clinical diagnosis of placenta previa is confirmed by trans vaginal ultrasound.
  • Placenta previa with preterm uterine contractions (< 3 contractions in 10 minutes)
  • Ability to provide informed consent.

Exclusion criteria

  • Placental abruption .
  • Women with placenta previa and severe attack of bleeding need immediate termination
  • Clinical criteria of intra uterine infection.
  • intrauterine growth restriction .
  • Fetal anomalies.
  • Fetal distress.
  • intrauterine fetal death.
  • Preterm rupture of membrane
  • High order multiple pregnancies.
  • Treatment with any tocolytic agent before maternal transport.
  • Inability or refusal to provide informed consent.
  • Women with any contraindication for use of magnesium sulfate as patients with renal failure.
  • Patients with bleeding disorder or on anticoagulant therapy .

Treatment and study plan

Magnesium sulfate

Drug

Patients will be assessed hourly for pulse and blood pressure, contraction frequency, vaginal bleeding. With strict monitoring for symptoms of magnesium sulfate toxicity.

All patients will receive dexamethasone to enhance fetal lung maturity. Rhesus factor status will be determined for all patients, . Hb level will be measured and anemic patients will receive correction by blood transfusion Cervical length will be measured after 24 h& 48 h from administration of magnesium sulfate in both groups Maternal serum magnesium will be measured at admission and after 4 hours ,12 hours and 24 hours after administration of magnesium sulfate Patients of both groups will be assessed for their neonatal outcomes include deaths and gestational age at delivery, fetal birth weight. Apgar score at five minutes, neonatal intensive care unit admission and duration of admission and neonatal calcium level at time of delivery will be also assessed.

Primary outcomes

  1. Evaluate efficacy (postponing delivery for 48h - till administration of dexamethasone ) of different regimens 0f MgSO4 in patients with pp in preterm . 2) Different regimens of MGSO4 and changes in cervical length

    Time frame: 48 hour

    comparing efficacy of low vs high dose of MgSO4 to postpone preterm delivery in patients with symptomatic pp and subsequent changes in cervical length

Secondary outcomes

  1. Gestational age at delivery

    Time frame: at time of delivery

  2. birth weight

    Time frame: at time of delivery

  3. number of full term babies

    Time frame: at time of delivery

  4. fetal and Neonatal death .

    Time frame: at time of delivery

  5. Apgar score at five minutes .

    Time frame: 5 minutes

  6. Neonatal intensive care unit admission & duration of admission

    Time frame: at time of delivery

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

High Versus Low Dose of Magnesium Sulfate as Initial Tocolytic Agent for Preterm Labour in Symptomatic Placenta Previa

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Oct 23, 2020
Registry last updated
Sep 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.